Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors—United States, July 2016–June 2019 | Zendy

Jeremy A.W. Gold | Zendy; Seda S. Tolu | Zendy; Tom Chiller | Zendy; Kaitlin Benedict | Zendy; Brendan R. Jackson | Zendy

Open Access

Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors—United States, July 2016–June 2019

Author(s) -

Jeremy A.W. Gold,

Seda S. Tolu,

Tom Chiller,

Kaitlin Benedict,

Brendan R. Jackson

Publication year - 2021

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciab1026

Subject(s) - ibrutinib , incidence (geometry) , medicine , small molecule , leukemia , biology , chronic lymphocytic leukemia , physics , optics , genetics

We analyzed administrative data to determine the 1-year incidence of invasive fungal infections (IFIs) in patients beginning small molecule kinase inhibitor (SMKI) therapy. The incidence of IFIs by small molecule kinase inhibitor ranged from 0.0% to 10.6%, with patients taking midostaurin having the highest incidence. An IFI developed in 38 of 1286 patients taking ibrutinib (3.0%).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research